摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2E)-3-(3-bromo-4-hydroxyphenyl)-2-[(oxan-2-yloxy)imino]-propanoic Acid

中文名称
——
中文别名
——
英文名称
(2E)-3-(3-bromo-4-hydroxyphenyl)-2-[(oxan-2-yloxy)imino]-propanoic Acid
英文别名
(E)-3-(3-bromo-4-hydroxyphenyl)-2-{[(tetrahydro-2H-pyran-2-yl)oxy]imino}propanoic acid;(2E)-3-(3-bromo-4-hydroxyphenyl)-2-(oxan-2-yloxyimino)propanoic acid
(2E)-3-(3-bromo-4-hydroxyphenyl)-2-[(oxan-2-yloxy)imino]-propanoic Acid化学式
CAS
——
化学式
C14H16BrNO5
mdl
——
分子量
358.189
InChiKey
VATRKDOFAKHTDJ-LFIBNONCSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    21
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    88.4
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    New synthetic strategies towards psammaplin A, access to natural product analogues for biological evaluation
    摘要:
    开发了新的合成路线以制备天然产物海绵抑素A(psammaplin A)及其多样化的类似物,这些类似物用于生物学评估。这些路线采用廉价且商业可获得的起始原料,并能合成目前报道方法难以获得的psammaplin A类似物。初步生物学研究表明,这些化合物是目前所发现的最强效的非肽类组蛋白去乙酰化酶1(HDAC1,I类)抑制剂。有趣的是,psammaplin A及其我们的合成类似物在体外显示出I类选择性,这对于设计和合成未来同工型选择性抑制剂具有重要意义。
    DOI:
    10.1039/c0ob00824a
  • 作为产物:
    参考文献:
    名称:
    New synthetic strategies towards psammaplin A, access to natural product analogues for biological evaluation
    摘要:
    开发了新的合成路线以制备天然产物海绵抑素A(psammaplin A)及其多样化的类似物,这些类似物用于生物学评估。这些路线采用廉价且商业可获得的起始原料,并能合成目前报道方法难以获得的psammaplin A类似物。初步生物学研究表明,这些化合物是目前所发现的最强效的非肽类组蛋白去乙酰化酶1(HDAC1,I类)抑制剂。有趣的是,psammaplin A及其我们的合成类似物在体外显示出I类选择性,这对于设计和合成未来同工型选择性抑制剂具有重要意义。
    DOI:
    10.1039/c0ob00824a
点击查看最新优质反应信息

文献信息

  • New synthetic strategies towards psammaplin A, access to natural product analogues for biological evaluation
    作者:Matthias G. J. Baud、Thomas Leiser、Franz-Josef Meyer-Almes、Matthew J. Fuchter
    DOI:10.1039/c0ob00824a
    日期:——
    New synthetic routes towards the natural product psammaplin A were developed with the particular view to preparing diverse analogues for biological assessment. These routes utilize cheap and commercially available starting materials, and allowed access to psammaplin A analogues not accessible via currently reported methods. Preliminary biological studies revealed these compounds to be the most potent non peptidic inhibitors of the enzyme histone deacetylase 1 (HDAC1, class I) discovered so far. Interestingly, psammaplin A and our synthetic analogues show class I selectivity in vitro, an important feature for the design and synthesis of future isoform selective inhibitors.
    开发了新的合成路线以制备天然产物海绵抑素A(psammaplin A)及其多样化的类似物,这些类似物用于生物学评估。这些路线采用廉价且商业可获得的起始原料,并能合成目前报道方法难以获得的psammaplin A类似物。初步生物学研究表明,这些化合物是目前所发现的最强效的非肽类组蛋白去乙酰化酶1(HDAC1,I类)抑制剂。有趣的是,psammaplin A及其我们的合成类似物在体外显示出I类选择性,这对于设计和合成未来同工型选择性抑制剂具有重要意义。
  • Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity
    作者:Hae Ju Han、Woong Sub Byun、Gyu Ho Lee、Won Kyung Kim、Kyungkuk Jang、Sehun Yang、Jewon Yang、Min Woo Ha、Suckchang Hong、Jeeyeon Lee、Jongheon Shin、Ki Bong Oh、Sang Kook Lee、Hyeung-geun Park
    DOI:10.1016/j.bmc.2021.116072
    日期:2021.4
    cells and inhibitory activity toward DOT1L for antitumor potential. All synthetic selenopsammaplin A analogues exhibited the higher cytotoxicity compared to psammaplin A with up to 6 – 60 times depending on cancer cells, and most analogues showed significant inhibitory activities against DOT1L. Among the prepared analogues, the phenyl analogue (10) possessed the most potent activity with both cytotoxicity
    Disruptor of telomer silencing-1 like (DOT1L) 是一种组蛋白 H3 甲基转移酶,可特异性催化组蛋白 H3 赖氨酸 79 残基的甲基化。最近的研究结果表明,DOT1L 异常过度表达,而上调的 DOT1L 引起人乳腺癌细胞的增殖和转移。因此,DOT1L 抑制剂被认为是治疗乳腺癌的一种有前景的策略。本研究首次报道了非核苷 DOT1L 抑制剂 selenopsammaplin A 及其类似物。Selenopsammaplin A 是新设计和合成的,由 3-bromo-4-hydroxybenzaldahyde 分 8 步以 25% 的总产率合成,并制备了 13 个 selenopsammaplin A 类似物,用于研究它们对癌细胞的细胞毒性和对 DOT1L 的抑制活性的构效关系研究。抗肿瘤潜力。与 psammaplin A 相比,所有合成的 selenopsammaplin
  • Combinatorial Synthesis through Disulfide Exchange: Discovery of Potent Psammaplin A Type Antibacterial Agents Active against Methicillin-ResistantStaphylococcus aureus (MRSA)
    作者:K. C. Nicolaou、Robert Hughes、Jeffrey A. Pfefferkorn、Sofia Barluenga、A. J. Roecker
    DOI:10.1002/1521-3765(20011001)7:19<4280::aid-chem4280>3.0.co;2-3
    日期:2001.10.1
    Psammaplin A is a symmetrical bromotyrosine -derived disulfide natural product isolated from the Psammaplysilla sponge, which exhibits in vitro antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). Inspired by the structure of this marine natural product, a combinatorial scrambling strategy for the construction of heterodimeric disulfide analogues was developed and applied to the construction of a 3828-membered library starting from 88 homodimeric disulfides. These psammaplin A analogues were screened directly against various gram positive bacterial strains leading to the discovery of a series of potent antibacterial agents active against methicillin-resistant Staphylococcus aureus (MRSA), Among the most active leads derived from these studies are compounds 104. 105, 113, 115, 123, and 128. The present, catalytically-induced. disulfide exchange strategy may be extendable to other types of building blocks bearing thiol groups facilitating the construction of diverse discovery-oriented combinatorial libraries.
  • EP3708563
    申请人:——
    公开号:——
    公开(公告)日:——
  • Efficient synthetic method of Psammaplin A
    作者:Suckchang Hong、Myungmo Lee、Myunggi Jung、Yohan Park、Mi-hyun Kim、Hyeung-geun Park
    DOI:10.1016/j.tetlet.2012.05.149
    日期:2012.8
    A new concise and efficient synthetic method of Psammaplin A was developed. Psammaplin A was obtained with 50% overall yield in nine steps from p-hydroxybenzaldehyde and ethyl acetoacetate via Knoevenagel condensation and direct nitrosation as key steps. This method might be very efficient to construct a quite diverse library of Psammaplin A type analogs. (C) 2012 Elsevier Ltd. All rights reserved.
查看更多